Drug-induced hypomagnesaemia : scope and management

Area of Science:

• Pharmacology
• Clinical Medicine
• Biochemistry

Background:

• Numerous medications are implicated in causing hypomagnesaemia, but clinical significance and frequency are often unclear.
• A comprehensive overview and standardized management guidelines for drug-induced hypomagnesaemia are lacking.
• Existing literature often overemphasizes or under-rates the hypomagnesaemic potential of various drugs.

Purpose of the Study:

• To comprehensively assess the clinical significance of hypomagnesaemia induced by various drugs.
• To propose a practical management approach for drug-induced hypomagnesaemia.
• To clarify monitoring and treatment strategies based on drug classification.

Main Methods:

• Systematic compilation of data from published literature, electronic databases, textbooks, and product information leaflets.
• Categorization of drugs based on the clinical significance of induced hypomagnesaemia.
• Development of a management strategy integrating literature evidence and clinical experience.

Main Results:

• Drugs like cisplatin, amphotericin B, and ciclosporin are classified as inducing 'significant' hypomagnesaemia, warranting routine monitoring and potential preventive treatment.
• Amikacin, gentamicin, laxatives, pentamidine, tobramycin, tacrolimus, and carboplatin are 'potentially significant,' requiring monitoring under specific clinical conditions.
• Drugs such as furosemide and hydrochlorothiazide have a 'questionable' hypomagnesaemic effect, not necessitating routine monitoring or treatment.

Conclusions:

• A tiered approach to managing drug-induced hypomagnesaemia is proposed, differentiating based on drug classification.
• Routine monitoring and proactive management are crucial for drugs with significant hypomagnesaemic potential.
• Judicious monitoring and treatment are recommended for potentially significant agents, while questionable agents require minimal intervention.